Key Points Bristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow. Eli Lilly and is seeing explosive revenue growth driven by its market-leading metabolic and injectable drug platforms. Should you prioritize value and dividends or high-octane pharmaceutical growth for your 2026 portfolio? 10 stocks we like better than Bristol Myers Squibb › Bristol Myers Squibb (NYSE:BMY) and Eli Lilly & Co (NYSE:LLY) represent two different paths in the healthcare market. Choosing between a deep-value dividend payer and a high-growth pharmaceutical juggernaut is the ultimate dilemma for investors today.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.